"Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K. In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230."@en . . . . "NS-2214"@en . . . . "Humans and other mammals"@en . . . . . . . . . . "For the treatment of Parkinson's Disease."@en . "Brasofensine is rapidly absorbed after oral administration in rats and monkeys, with peak plasma concentrations occurring 0.5-1 hr, but 3-8 hr for brasofensine in humans."@en . . . . . . . . . . . "171655-91-7"@en . . "# Zhu M, Whigan DB, Chang SY, Dockens RC: Disposition and Metabolism of [14C]Brasofensine in Rats, Monkeys and Humans. Drug Metab Dispos. 2007 Oct 1;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17908924 # Johnston TH, Brotchie JM: Drugs in development for Parkinson's disease. Curr Opin Investig Drugs. 2004 Jul;5(7):720-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15298067 # Frackiewicz EJ, Jhee SS, Shiovitz TM, Webster J, Topham C, Dockens RC, Whigan D, Salazar DE, Cutler NR: Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. Ann Pharmacother. 2002 Feb;36(2):225-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11847938"@en . . "Brasofensine"@en . . . . "When the neurotransmitter dopamine is released into the synaptic cleft, brasofensine prevents it from entering back into the source nerve cell, thereby allowing a longer period of synaptic activity."@en . . "Plasma terminal elimination half-lives were ~2 hr in rats, ~4 hr in monkeys, but ~24 hr in humans."@en . . "investigational"@en .